Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 1.04 (2.76%)
Data as of 07/17/18 12:52 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $38.74 with a 52 week high of $46.18 and a 52 week low of $15.74.
Recent NewsMore >>
Audentes Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to AT132 for the treatment of X-Linked Myotubular Myopathy
Audentes Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Andrew H. Chang
Director, Investor Relations
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.